BACKGROUND: Despite numerous therapeutic options, the treatment of verruca plana remains unsatisfactory for both patients and physicians. Imiquimod, a novel topical immune response modifier, has been successfully used for the treatment of external anogenital warts. OBJECTIVE: The purpose of this study was to investigate the efficacy of imiquimod in treatment of verruca plana. METHOD: Fifteen patients with verruca plana were treated with 5% imiquimod cream that was self-applied 3 times a week and left in place overnight. Assessment for responses and side effects was performed every 2 weeks until clinical cure or up to 12 weeks. RESULTS: 10 of 15 (66.7%) patients achieved a excellent result (>75% improvement), and 11 (73%) patients achieved a good result (>50% improvement). With regard to the location of the lesions, 10 of 12 (83%) patients with lesions on the face and neck achieved a clear result (>95% improvement), but only 2 of 7 (28%) patients with lesions on the extremities achieved a clear result. Local inflammatory reactions were the most common adverse events, however, they were generally mild and transient. CONCLUSION: 5% imiquimod cream, applied by the patient, is an effective treatment modality for verruca plana.
DOI 인용 스타일